

21/08/2007,10580183c.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXY1626

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'HCAPLUS' AT 14:37:48 ON 21 AUG 2007  
FILE 'HCAPLUS' ENTERED AT 14:37:48 ON 21 AUG 2007  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	13.14	185.45
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56
=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	13.14	185.45
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

FILE 'REGISTRY' ENTERED AT 14:38:03 ON 21 AUG 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 AUG 2007 HIGHEST RN 945102-95-4  
DICTIONARY FILE UPDATES: 20 AUG 2007 HIGHEST RN 945102-95-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10580183c.str

Young, Shawquia, Page 1



chain nodes :  
10 11 18 19 20  
ring nodes :  
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17  
chain bonds :  
1-10 2-11 11-12 18-19 18-20  
ring bonds :  
1-2 1-5 2-3 3-4 3-6 4-5 4-9 6-7 7-8 8-9 12-13 12-17 13-14 14-15 15-16  
16-17  
exact/norm bonds :  
1-2 1-5 1-10 2-3 2-11 4-5 18-19 18-20  
exact bonds :  
11-12  
normalized bonds :  
3-4 3-6 4-9 6-7 7-8 8-9 12-13 12-17 13-14 14-15 15-16 16-17


Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS  
20:CLASS 21:Atom

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 15

SAMPLE SEARCH INITIATED 14:38:19 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 461 TO ITERATE

100.0% PROCESSED 461 ITERATIONS 3 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 7932 TO 10508  
PROJECTED ANSWERS: 3 TO 163

L6 3 SEA SSS SAM L5

=> s 15 full

FULL SEARCH INITIATED 14:38:23 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 8705 TO ITERATE

100.0% PROCESSED 8705 ITERATIONS 106 ANSWERS  
SEARCH TIME: 00.00.01

L7 106 SEA SSS FUL L5

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	357.55
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.56

FILE 'HCAPLUS' ENTERED AT 14:38:27 ON 21 AUG 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

21/08/2007,10580183c.trn

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Aug 2007 VOL 147 ISS 9  
FILE LAST UPDATED: 20 Aug 2007 (20070820/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 17

L8                    3 L7


=> d ed abs ibib hitstr tot

L8 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ED Entered STN: 23 Jun 2006  
 AB Comps. for use as histone deacetylase inhibitors and their use to treat various diseases, including cancer, inflammation, and arthritis, are disclosed. Thus, a large number of benzimidazol-2-one derivs. are provided.  
 General procedures for synthesis of these types of compds. are described.  
 ACCESSION NUMBER: 2006:608746 HCAPLUS  
 DOCUMENT NUMBER: 145:78748  
 TITLE: Histone deacetylase inhibitors for use as antitumor, antiarthritic, and anti-Alzheimer drugs  
 INVENTOR(S): Bressi, Jerom C.; Brown, Jason W.; Gangloff, Anthony R.; Jennings, Andrew J.; Kaldor, Stephen W.; Skene, Robert J.; Stafford, Jeffrey A.; Vu, Phong H.  
 PATENT ASSIGNEE(S): Takeda San Diego, Inc., USA  
 SOURCE: PCT Int. Appl., 257 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006066133	A2	20060622	WO 2005-0945779	20051216
WO 2006066133	A3	20060831		
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, CN, CO, GW, ML, MR, NE, SN, TD, TO, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006205941	A1	20060914	US 2005-303455	20051216
PRIORITY APPLN. INFO.:			US 2004-636974P	P 20041216

OTHER SOURCE(S): MARPAT 145:78748  
 IT 890783-16-1P  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (histone deacetylase inhibitors for use as antitumor, antiarthritic, and anti-Alzheimer drugs)  
 RN 890783-16-1 HCAPLUS  
 CN Benzamide, 4-[(2-amino-1H-benzimidazol-1-yl)methyl]-N-(2-aminophenyl)-(9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ED Entered STN: 22 Jul 2005  
 GI



AB Title compds. I [R1 = OH, halo, carboxy, etc.; R2 = H, OH, halo, carboxy, carboxamido, etc.; R3 = alkyl, alkenyl, aryl, etc.; R4 = aryl, heterocyclyl, etc.; R5 = H, alkyl, R6 = H, OH, F, alkyl, R7 = H, F, etc.; R8 = H, alkyl, R9 = H, halo, OH, alkyl, etc.; n = 0-6; m = 0-2; Z = carboxy, 5-tetrazolyl, etc.] are prepared. For instance, 4-[(5,6-dichloro-2-methyl-2-[(4-(trifluoromethoxy)phenyl)imino]-2,3-dihydro-1H-benzimidazol-1-yl)methyl]-N-(1H-tetrazol-5-yl)benzamide is prepared in 5 steps from 4,5-dichloro-2-nitroaniline, 4-(trifluoromethoxy)phenylisothiocyanate and Me 4-(bromomethyl)benzoate. I are glucagon receptor antagonists [no data] useful for treating, preventing or delaying the onset of type 2 diabetes mellitus.

ACCESSION NUMBER: 2005:638732 HCAPLUS  
 DOCUMENT NUMBER: 143:153372  
 TITLE: Preparation of cyclic guanidines as glucagon receptor antagonists for the treatment of type 2 diabetes  
 INVENTOR(S): Parmee, Emma R.; Kim, Ronald M.; Rouse, Elizabeth A.; Schmidt, Darby R.; Sinz, Christopher Joseph; Chang, Jiang  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
 SOURCE: PCT Int. Appl., 111 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005065680	A1	20050721	WO 2004-042068	20041215
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004312001	A1	20050721	AU 2004-312001	20041215


L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CA 2547785 A1 20050721 CA 2004-2547785 20041215  
 EP 1699453 A1 20060913 EP 2004-814273 20041215  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, ER, HU, PL, SK, IS  
 CN 1897936 A 20070117 CN 2004-80038081 20041215  
 JP 2007514794 T 20070607 JP 2006-549288 20041215  
 IN 2006DN2846 A 20070803 IN 2006-DN2846 20060518  
 US 2007105930 A1 20070510 US 2006-580183 20060522  
 PRIORITY APPLN. INFO.:

OTHER SOURCE(S): CASREACT 143:153372; MARPAT 143:153372  
 IT 859876-01-0P 859876-02-1P 859876-03-2P  
 859876-04-3P 859876-05-4P 859876-06-5P  
 859876-07-6P 859876-08-7P 859876-09-8P  
 859876-10-1P 859876-11-2P 859876-12-3P  
 859876-13-4P 859876-14-5P 859876-15-6P  
 859876-16-7P 859876-17-8P 859876-18-9P  
 859876-19-0P 859876-20-3P 859876-21-4P  
 859876-22-5P 859876-23-6P 859876-24-7P  
 859876-25-8P 859876-26-9P 859876-27-0P  
 859876-28-1P 859876-29-2P 859876-30-5P  
 859876-31-6P 859876-32-7P 859876-33-8P  
 859876-34-9P 859876-35-0P 859876-36-1P  
 859876-37-2P 859876-38-3P 859876-39-4P  
 859876-40-7P 859876-41-8P 859876-42-9P  
 859876-43-0P 859876-44-1P 859876-45-2P  
 859876-46-3P 859876-47-4P 859876-48-5P  
 859876-49-6P 859876-50-9P 859876-51-0P  
 859876-52-1P 859876-53-2P 859876-54-3P  
 859876-55-4P 859876-56-5P 859876-57-6P  
 859876-58-7P 859876-59-8P 859876-60-1P  
 859876-61-2P 859876-62-3P 859876-63-4P  
 859876-64-5P 859876-65-6P 859876-66-7P  
 859876-67-8P 859876-68-9P 859876-69-0P  
 859876-70-3P 859876-71-4P 859876-72-5P  
 859876-73-6P 859876-74-7P 859876-75-8P  
 859876-76-9P 859876-77-0P 859876-78-1P  
 859876-79-2P 859876-80-5P 859876-81-6P  
 859876-82-7P 859876-83-8P 859876-84-9P  
 859876-85-0P 859876-86-1P 859876-87-2P  
 859876-88-3P 859876-89-4P 859876-90-7P  
 859876-91-8P 859876-92-9P 859876-93-0P  
 859876-94-1P 859876-95-2P 859876-96-3P  
 859876-97-4P 859876-98-5P 859876-99-6P  
 859877-00-2P 859877-01-3P 859877-02-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of cyclic guanidines as glucagon receptor antagonists for treatment of type 2 diabetes)  
 RN 859876-01-0 HCAPLUS  
 CN Benzamide, 4-[(5,6-dichloro-2,3-dihydro-3-methyl-2-[(4-(trifluoromethoxy)phenyl)imino]-1H-benzimidazol-1-yl)methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

21/08/2007,10580183c.trn

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-02-1 HCAPLUS  
CN  $\beta$ -Alanine, N-[4-[[5,6-dichloro-2,3-dihydro-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]benzoyl]- (9CI) (CA INDEX NAME)





RN 859876-03-2 HCAPLUS  
CN Benzamide, 4-[[5,6-dichloro-2,3-dihydro-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-(1H-tetrazol-5-ylmethyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-04-3 HCAPLUS  
CN Benzamide, 4-[[5,6-dichloro-2-[[4-(cyclohexylphenyl)imino]-2,3-dihydro-3-methyl-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 859876-05-4 HCAPLUS  
CN Benzamide, 4-[[6-chloro-2,3-dihydro-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-06-5 HCAPLUS  
CN Benzamide, 4-[[2-[[4-[[1,1-dimethylethyl]phenyl]imino]-2,3-dihydro-3-methyl-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 859876-07-6 HCAPLUS  
CN Benzamide, 4-[[4-bromo-2,3-dihydro-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-08-7 HCAPLUS  
CN Benzamide, 4-[[4-ethenyl-2,3-dihydro-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 859876-09-8 HCAPLUS  
CN Benzamide, 4-[[4-ethyl-2,3-dihydro-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl]- (9CI) (CA INDEX NAME)

21/08/2007,10580183c.trn

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-10-1 HCAPLUS  
CN Benzamide, 4-[[2,3-dihydro-3-methyl-4-(methylsulfonyl)-2-[[4-(trifluoromethoxy)phenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-11-2 HCAPLUS  
CN Benzamide, 4-[[2,3-dihydro-3,4-dimethyl-2-[[4-(trifluoromethoxy)phenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-14-5 HCAPLUS  
CN Benzamide, 4-[[5,6-dichloro-2,3-dihydro-3-methyl-2-[[4-(2-propenyloxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-15-6 HCAPLUS  
CN Benzamide, 4-[[5,6-dichloro-2,3-dihydro-2-[[4-(4-hydroxyphenyl)imino]-3-methyl-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-12-3 HCAPLUS  
CN Benzamide, 4-[[5-chloro-2,3-dihydro-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-13-4 HCAPLUS  
CN Benzamide, 4-[[5,6-dichloro-2,3-dihydro-3-methyl-2-[[3-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-16-7 HCAPLUS  
CN Benzamide, 4-[[5,6-dichloro-2,3-dihydro-3-methyl-2-[[4-(4-propoxyphenyl)imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-17-8 HCAPLUS  
CN Benzamide, 4-[[2-[[3-bromo-4-(trifluoromethoxy)phenyl]imino]-5,6-dichloro-2,3-dihydro-3-methyl-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

21/08/2007,10580183c.trn

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-18-9 HCAPLUS  
CN Benzamide, 4-[[2,3-dihydro-3-methyl-5-propoxy-2-[[4-(3-thienyl)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-19-0 HCAPLUS  
CN Benzamide, 4-[[5,6-dichloro-2,3-dihydro-2-[[4-methoxyphenyl]imino]-3-methyl-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-22-5 HCAPLUS  
CN Benzamide, 4-[[6-chloro-4-ethoxy-2,3-dihydro-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-23-6 HCAPLUS  
CN Benzamide, 4-[[2-[[3,5-dichlorophenyl]imino]-2,3-dihydro-3-methyl-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-20-3 HCAPLUS  
CN Benzamide, 4-[[5,6-dichloro-2-[[4-(cyclopentyloxy)phenyl]imino]-2,3-dihydro-3-methyl-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-21-4 HCAPLUS  
CN Benzamide, 4-[[6-chloro-2,3-dihydro-4-methoxy-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 859876-24-7 HCAPLUS  
CN Benzamide, 4-[[2-[[3,5-dichlorophenyl]imino]-2,3-dihydro-6-methoxy-3-methyl-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-25-8 HCAPLUS  
CN Benzamide, 4-[[2-[[4-(1-cyclohexen-1-yl)phenyl]imino]-2,3-dihydro-3-methyl-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




21/08/2007,10580183c.trn

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-26-9 HCAPLUS  
CN Benzamide, 4-[[2,3-dihydro-3-methyl-6-(trifluoromethoxy)-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-27-0 HCAPLUS  
CN Benzamide, 4-[[2,3-dihydro-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-30-5 HCAPLUS  
CN Benzamide, 4-[[2,3-dihydro-3-methyl-6-propoxy-2-[[4-(trifluoromethyl)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-31-6 HCAPLUS  
CN Benzamide, 4-[[2,3-dihydro-3-methyl-6-(trifluoromethyl)-2-[[3-(trifluoromethyl)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-28-1 HCAPLUS  
CN Benzamide, 4-[[4,6-dichloro-2,3-dihydro-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-29-2 HCAPLUS  
CN Benzamide, 4-[[2-[[4-chlorophenyl]imino]-2,3-dihydro-3-methyl-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-32-7 HCAPLUS  
CN Benzamide, 4-[[2,3-dihydro-3-methyl-6-(trifluoromethyl)-2-[[4-(trifluoromethyl)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-33-8 HCAPLUS  
CN Benzamide, 4-[[4-chloro-2,3-dihydro-3-methyl-2-[[4-(trifluoromethyl)phenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-34-9 HCAPLUS  
 CN Benzamide, 4-[[5,6-dichloro-2-[[4-(cyclopentylmethoxy)phenyl]imino]-2,3-dihydro-3-methyl-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI)  
 (CA INDEX NAME)




RN 859876-35-0 HCAPLUS  
 CN Benzamide, 4-[[5,6-dichloro-2,3-dihydro-3-methyl-2-[[4-(1-methylethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI)  
 (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-36-1 HCAPLUS  
 CN Benzamide, 4-[[5,6-dichloro-2,3-dihydro-3-methyl-2-[[4-(phenylmethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI)  
 (CA INDEX NAME)




RN 859876-37-2 HCAPLUS  
 CN Benzamide, 4-[[5,6-dichloro-2-[[4-(1,1-dimethylethyl)phenyl]imino]-2,3-dihydro-3-methyl-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI)  
 (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-38-3 HCAPLUS  
 CN Benzamide, 4-[[5,6-dichloro-2,3-dihydro-3-methyl-2-[[4-(trifluoromethyl)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI)  
 (CA INDEX NAME)




RN 859876-39-4 HCAPLUS  
 CN Benzamide, 4-[[2,3-dihydro-6-methoxy-3-methyl-2-[[4-(3,3,5,5-tetramethylcyclohexyl)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI)  
 (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-40-7 HCAPLUS  
 CN Benzamide, 4-[[2-[[4-(4,4-difluorocyclohexyl)phenyl]imino]-2,3-dihydro-6-methoxy-3-methyl-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI)  
 (CA INDEX NAME)




RN 859876-41-8 HCAPLUS  
 CN Benzamide, 4-[[2,3-dihydro-3-methyl-5-propoxy-2-[[4-(2,2,2-trifluoroethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI)  
 (CA INDEX NAME)

21/08/2007,10580183c.trn

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-42-9 HCAPLUS  
CN Benzamide, 4-[[[4-butoxy-6-chloro-2,3-dihydro-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl)methyl]-N-1H-tetrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 859876-43-0 HCAPLUS  
CN Benzamide, 4-[[[5,6-dichloro-2-[[3,4-dichlorophenyl]imino]-2,3-dihydro-3-methyl-1H-benzimidazol-1-yl)methyl]-N-1H-tetrazol-5-yl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-44-1 HCAPLUS  
CN Benzamide, 4-[[[2,3-dihydro-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-4,5-bis(trifluoromethyl)-1H-benzimidazol-1-yl)methyl]-N-1H-tetrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 859876-45-2 HCAPLUS  
CN Benzamide, 4-[[[2,3-dihydro-3-methyl-2-[[4-(3,3,5,5-tetramethylcyclohexyl)phenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-yl)methyl]-N-1H-tetrazol-5-yl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-46-3 HCAPLUS  
CN Benzamide, 4-[[[2,3-dihydro-6-methoxy-3-methyl-2-[[4-(tricyclo[3.3.1.1.3,7]dec-1-yl)phenyl]imino]-1H-benzimidazol-1-yl)methyl]-N-1H-tetrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 859876-47-4 HCAPLUS  
CN Benzamide, 4-[[[6-chloro-2-[[4-(cyclohexyl)phenyl]imino]-2,3-dihydro-4-methoxy-3-methyl-1H-benzimidazol-1-yl)methyl]-N-1H-tetrazol-5-yl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-48-5 HCAPLUS  
CN Benzamide, 4-[[[2-[[[4-(2,2-difluoroethyl)phenyl]imino]-2,3-dihydro-3-methyl-5-propoxy-1H-benzimidazol-1-yl)methyl]-N-1H-tetrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 859876-49-6 HCAPLUS  
CN Benzamide, 4-[[[2-[[[4-(4-butylphenyl)imino]-2,3-dihydro-3-methyl-6-(trifluoromethyl)-1H-benzimidazol-1-yl)methyl]-N-1H-tetrazol-5-yl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-50-9 HCAPLUS  
 CN Benzamide,  
 4-[[2-[[4-(1,1-dimethylethyl)phenyl]imino]-4-ethyl-2,3-dihydro-3-methyl-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-51-0 HCAPLUS  
 CN Benzamide,  
 4-[[4-ethyl-2-[[4-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-55-4 HCAPLUS  
 CN Benzamide,  
 4-[[6-chloro-2-[[4-(1,1-dimethylethyl)phenyl]imino]-2,3-dihydro-4-methoxy-3-methyl-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-56-5 HCAPLUS  
 CN Benzamide,  
 4-[[2-[[4-(2,4-dimethylcyclopentyl)phenyl]imino]-2,3-dihydro-3-methyl-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 859876-52-1 HCAPLUS  
 CN Benzamide,  
 4-[[6-chloro-2,3-dihydro-3-methyl-4-propoxy-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)





RN 859876-53-2 HCAPLUS  
 CN Benzamide,  
 4-[[6-chloro-2,3-dihydro-3-methyl-4-(1-methylethoxy)-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)





RN 859876-54-3 HCAPLUS  
 CN Benzamide,  
 4-[[2,3-dihydro-3-methyl-4-phenyl-2-[[4-(trifluoromethoxy)phenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-57-6 HCAPLUS  
 CN Benzamide,  
 4-[[2-[[4-(2,4-dimethylcyclopentyl)phenyl]imino]-2,3-dihydro-6-methoxy-3-methyl-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-58-7 HCAPLUS  
 CN Benzamide,  
 4-[[4-ethyl-2,3-dihydro-3-methyl-2-[[4-methylphenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-59-8 HCAPLUS  
 CN Benzamide, 4-[[4-ethyl-2,3-dihydro-3-methyl-2-[[4-(1-methylethyl)phenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-60-1 HCAPLUS  
 CN Benzamide, 4-[[4-butoxy-2,3-dihydro-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-63-4 HCAPLUS  
 CN Benzamide, 4-[[6-chloro-2,3-dihydro-4-hydroxy-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-64-5 HCAPLUS  
 CN Benzamide, 4-[[2,3-dihydro-4-methoxy-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-61-2 HCAPLUS  
 CN Benzamide, 4-[[2-[[4-cyclohexylphenyl]imino]-6-fluoro-2,3-dihydro-3-methyl-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-62-3 HCAPLUS  
 CN Benzamide, 4-[[6-chloro-2-[[3-chloro-4-(trifluoromethoxy)phenyl]imino]-2,3-dihydro-4-methoxy-3-methyl-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-65-6 HCAPLUS  
 CN Benzamide, 4-[[2,3-dihydro-3-methyl-4-propoxy-2-[[4-(trifluoromethoxy)phenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-66-7 HCAPLUS  
 CN Benzamide, 4-[[2,3-dihydro-6-methoxy-3-methyl-2-[[3-methyl-4-(1-methylethyl)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-67-8 HCAPLUS  
 CN Benzamide, 4-[[2,3-dihydro-3-methyl-2-[[3-methyl-4-(1-methylethyl)phenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-68-9 HCAPLUS  
 CN Benzamide, 4-[[2-[[4-(1,1-dimethylethyl)phenyl]imino]-2,3-dihydro-4-methoxy-3-methyl-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-71-4 HCAPLUS  
 CN Benzamide, 4-[[4-ethoxy-2,3-dihydro-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-72-5 HCAPLUS  
 CN β-Alanine, N-[4-[[2-[[3,5-dichlorophenyl]imino]-2,3-dihydro-6-methoxy-3-methyl-1H-benzimidazol-1-yl]methyl]benzoyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-69-0 HCAPLUS  
 CN Benzamide, 4-[[2-[[4-(1,1-dimethylethyl)phenyl]imino]-2,3-dihydro-3-methyl-4-propoxy-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-70-3 HCAPLUS  
 CN Benzamide, 4-[[2,3-dihydro-3-methyl-4-propoxy-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 859876-73-6 HCAPLUS  
 CN β-Alanine, N-[4-[[5-chloro-2,3-dihydro-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 859876-74-7 HCAPLUS  
 CN β-Alanine, N-[4-[[5,6-dichloro-2-[[4-(cyclohexyl)phenyl]imino]-2,3-dihydro-3-methyl-1H-benzimidazol-1-yl]methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 859876-75-8 HCAPLUS  
 CN β-Alanine, N-[4-[[2-[[4-chlorophenyl]imino]-2,3-dihydro-3-methyl-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]benzoyl]- (9CI) (CA INDEX NAME)

21/08/2007,10580183c.trn

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-76-9 HCAPLUS  
CN  $\beta$ -Alanine, N-[4-[[2,3-dihydro-3-methyl-6-(trifluoromethyl)-2-[[4-(trifluoromethyl)phenyl]imino]-1H-benzimidazol-1-yl]methyl]benzoyl]-  
(9CI) (CA INDEX NAME)




RN 859876-77-0 HCAPLUS  
CN  $\beta$ -Alanine, N-[4-[[2,3-dihydro-3-methyl-6-(trifluoromethyl)-2-[[4-(trifluoromethyl)phenyl]imino]-1H-benzimidazol-1-yl]methyl]benzoyl]-  
(9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-80-5 HCAPLUS  
CN Benzamide, 4-[[5,6-dichloro-2,3-dihydro-3-propyl-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-  
5-yl- (9CI) (CA INDEX NAME)




RN 859876-81-6 HCAPLUS  
CN Benzamide, 4-[[5,6-dichloro-2,3-dihydro-3-(phenylmethyl)-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-  
5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-78-1 HCAPLUS  
CN  $\beta$ -Alanine, N-[4-[[2,3-dihydro-3-methyl-4-propoxy-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]benzoyl]-  
(9CI) (CA INDEX NAME)




RN 859876-79-2 HCAPLUS  
CN Benzamide, 4-[[5,6-dichloro-3-ethyl-2,3-dihydro-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-  
5-yl- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 859876-82-7 HCAPLUS  
CN Benzamide, 4-[[5,6-dichloro-2,3-dihydro-3-(1-methylethyl)-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-  
5-yl- (9CI) (CA INDEX NAME)




RN 859876-83-8 HCAPLUS  
CN Benzamide, 4-[[5,6-dichloro-3-(2-fluoroethyl)-2,3-dihydro-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-  
5-yl- (9CI) (CA INDEX NAME)




RN 859876-84-9 HCAPLUS  
CN Benzamide, 4-[[5,6-dichloro-3-[2-(dimethylamino)ethyl]-2,3-dihydro-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-  
5-yl- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 859876-85-0 HCAPLUS  
 CN Benzamide, 4-[[5,6-dichloro-2,3-dihydro-3-(2-methoxyethyl)-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-86-1 HCAPLUS  
 CN Benzamide, 4-[[5,6-dichloro-2,3-dihydro-3-(3-methoxypropyl)-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-87-2 HCAPLUS  
 CN Benzamide, 4-[[5,6-dichloro-3-(3-(dimethylamino)propyl)-2,3-dihydro-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-90-7 HCAPLUS  
 CN Benzamide, 4-[[2-[[3-bromo-4-(trifluoromethoxy)phenyl]imino]-5,6-dichloro-3-ethyl-2,3-dihydro-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)





RN 859876-91-8 HCAPLUS  
 CN Benzamide, 4-[[5,6-dichloro-2-[[2,3-dihydro-1H-inden-5-yl]imino]-2,3-dihydro-3-methyl-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-88-3 HCAPLUS  
 CN Benzamide, 4-[[1-[[5,6-dichloro-2,3-dihydro-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]ethyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-89-4 HCAPLUS  
 CN Benzamide, 4-[[3-ethyl-2,3-dihydro-2-[[4-(trifluoromethoxy)phenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 859876-92-9 HCAPLUS  
 CN Benzamide, 4-[[2-[[2,3-dihydro-1H-inden-5-yl]imino]-4-ethyl-2,3-dihydro-3-methyl-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)



RN 859876-93-0 HCAPLUS  
 CN Benzamide, 4-[[3,4-diethyl-2,3-dihydro-2-[[4-(trifluoromethoxy)phenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-94-1 HCAPLUS  
 CN Benzamide, 4-[[2-[[4-(1,1-dimethylethyl)phenyl]imino]-3,4-diethyl-2,3-dihydro-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




21/08/2007,10580183c.trn

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-95-2 HCAPLUS  
CN Benzamide, 4-[[6-chloro-3-ethyl-2,3-dihydro-4-propoxy-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-96-3 HCAPLUS  
CN Benzamide, 4-[[5-chloro-2,3-dihydro-3-methyl-2-[[4-(trifluoromethoxy)phenyl]imino]-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-99-6 HCAPLUS  
CN Benzamide, 4-[[2-[[4-(3,4-dimethylcyclopentyl)phenyl]imino]-2,3-dihydro-3-methyl-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859877-00-2 HCAPLUS  
CN Benzamide, 4-[[2-[[4-(3,4-dimethylcyclopentyl)phenyl]imino]-2,3-dihydro-6-methoxy-3-methyl-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859876-97-4 HCAPLUS  
CN Benzamide, 4-[[5,6-dichloro-2-[[3,5-dichlorophenyl]imino]-2,3-dihydro-3-methyl-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859876-98-5 HCAPLUS  
CN Benzamide, 4-[[2-[[4-(cyclohexylphenyl)imino]-2,3-dihydro-3-methyl-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 859877-01-3 HCAPLUS  
CN Benzamide, 4-[[2-[[4-(1,1-dimethylethyl)-3-methylphenyl]imino]-2,3-dihydro-4-methoxy-3-methyl-6-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 859877-02-4 HCAPLUS  
CN Benzamide, N-[[4-[[6-chloro-3-ethyl-2,3-dihydro-4-propoxy-2-[[4-(trifluoromethoxy)phenyl]imino]-1H-benzimidazol-1-yl]methyl]benzoyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L8 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN  
ED Entered STN: 08 Nov 2002  
QI



AB The title compds. I [ring C is a benzene ring, a pyridine ring, or the like; R1 is optionally substituted C1-6 alkyl or the like; R201 is hydrogen, halogeno, acyl, or the like; R6 is hydrogen, C1-6 alkyl, C1-6 alkylcarbonyl, or the like; Y1 is a single bond, CH2, or the like; Y2 is a single bond, CO, or the like; and Ar is hydrogen, Ph (generic structure given) (further details on said Ph are given)] are prepared

2-[3-(4-Aminobenzyl)-2-imino-2,3-dihydrobenzimidazol-1-yl]-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone dihydrochloride in vitro showed IC50 of 1.3

$\mu$ M against thrombin-induced platelet aggregation.  
ACCESSION NUMBER: 2002:849601 HCAPLUS  
DOCUMENT NUMBER: 137:353024  
TITLE: Preparation of 2-iminoimidazole derivatives as platelet aggregation inhibitors  
INVENTOR(S): Suzuki, Shuichi; Kotake, Makoto; Miyamoto, Mitsuaki; Kawahara, Tetsuya; Kajiwara, Akiharu; Hishinuma, Ieharu; Okano, Kazuo; Miyazawa, Syuhei; Clark, Richard; Ozaki, Fumihiro; Sato, Nobuaki; Shinoda, Masanobu; Kamada, Atsushi; Tsukada, Itaru; Matsura, Fumiyoshi; Naoe, Yoshimitsu; Terauchi, Taro; Ohashi, Yoshiaki; Ito, Osamu; Tanaka, Hiroshi; Mutsaers, Takashi; Kogushi, Motoji; Kawada, Tsutomu; Matsuoka, Toshiyuki; Kobayashi, Hiroko; Chiba, Kenichi; Kimura, Akifumi; Ono, Naoto  
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 225 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 4  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------


L8 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

WO 2002088094 A1 20021107 WO 2002-JP3952 20020419  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, HM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO  
AU 2002251501 A1 20021111 AU 2002-251501 20020419  
EP 1394152 A1 20040303 EP 2002-720536 20020419  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
CN 1503784 A 20040609 CN 2002-808565 20020419  
EP 1614680 A2 20060111 EP 2005-22069 20020419  
EP 1614680 A3 20060201  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR  
CN 1733725 A 20060215 CN 2005-10080404 20020419  
CN 1754880 A 20060405 CN 2005-10080403 20020419  
ZA 200308064 A 20050207 ZA 2003-8064 20031016  
US 2004242627 A1 20041202 US 2004-475045 20040611  
JP 2006206595 A 20060810 JP 2006-41270 20060217  
JP 2006225393 A 20060831 JP 2006-41255 20060217  
JP 2001-121829 A 20010419  
JP 2001-269422 A 20010905  
CN 2002-808565 A3 20020419  
EP 2002-724628 A3 20020419  
JP 2002-583382 A3 20020419  
WO 2002-JP3952 W 20020419

PRIORITY APPLN. INFO.:


OTHER SOURCE(S): MARPAT 137:353024  
IT 474829-07-7P 474829-19-1P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 2-iminoimidazole derivate as platelet aggregation inhibitors)  
RN 474829-07-7 HCAPLUS  
CN Benzamide, 3-[(3-[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-2-oxoethyl]-2,3-dihydro-2-imino-1H-benzimidazol-1-yl)methyl]-, monohydrobromide (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HBr

RN 474829-19-1 HCAPLUS  
CN Benzamide, 3-[(3-[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-2-oxoethyl]-2,3-dihydro-2-imino-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT